Extent of CMS Coverage for Leqembi Treatment Still Uncertain, Clinicians Say

Although Medicare will now cover antiamyloid antibodies fully approved for early Alzheimer’s and the PET imaging required to qualify for them, questions remain about how coverage will shake out for other procedures that clinicians deem necessary for these treatment regimens.
Source: Drug Industry Daily